PEP: Personalizing Exercise for Parkinson Disease

Sponsor
Washington University School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT04782518
Collaborator
(none)
1,000
1
48
20.8

Study Details

Study Description

Brief Summary

The overarching aim is to determine the benefits of Parkinson-specific exercise programs and general exercise patterns on physical function and disease-related quality of life among people with Parkinson Disease (PD). The significance of this project is that millions of individuals experience adverse consequences of PD and there is strong evidence that structured exercise programs have beneficial effects on motor function and PD-related quality of life. Participation in this study involves online surveys upon enrollment (i.e., baseline) and at 3 months, 6 months, 9 months, 1 year, and 2 years.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Parkinson Disease (PD) is a neurodegenerative disease that affects more than ten million people worldwide. In the United States, more than one million people are living with PD and more than 100,000 new cases are diagnosed each year.

    Exercise to Ease the Burden of PD:

    Exercise is an adjunct to pharmacologic therapy for PD that has been shown in many intensive research studies to help improve motor and non-motor symptoms in PD. A variety of Parkinson-specific exercise programs have been developed to help improve balance, posture, mobility, strength, endurance, speech, and/or self-help skills. These classes include various modes of exercise and different intensity levels, tailored for patients' personal characteristics and functional abilities.

    Current Gaps in Knowledge and Aim:

    The benefits of PD-specific exercise programs on physical function and disease-related quality of life have not been evaluated. Furthermore, many patients may not have access to PD-specific exercise programs. The proposed project addresses these gaps by exploring associations between PD-specific exercise programs and several metrics of physical function and quality of life among individuals with PD. In addition, the investigators are studying associations among overall exercise patterns, physical activity patterns, physical function, and quality of life among individuals with PD.

    Study Involvement:

    Participation in this study involves online surveys completed upon enrollment (i.e., baseline) and at 3 months, 6 months, 9 months, 1 year, and 2 years. A family member, caregiver, or friend may help the participant complete the online surveys.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Personalizing Exercise for Parkinson Disease
    Actual Study Start Date :
    Feb 19, 2021
    Anticipated Primary Completion Date :
    Feb 18, 2024
    Anticipated Study Completion Date :
    Feb 18, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    Participants with PD

    Adults with Parkinson Disease. This is an observational study without an intervention.

    Outcome Measures

    Primary Outcome Measures

    1. Association between exercise patterns and quality of life [Baseline]

      Association between exercise patterns (including exercise type and frequency) and quality of life, as assessed by the Parkinson's Disease Questionnaire (PDQ-39). The score range for the PDQ-39 is 0 to 100, with lower scores reflecting higher quality of life.

    2. Association between exercise patterns and mobility [Baseline]

      Association between exercise patterns (including exercise type and frequency) and mobility, as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire. The Neuro-QOL short form domain on Lower Extremity Function - Mobility will be used. The score range for the Neuro-QOL Mobility domain is 8 to 40, with higher scores reflecting a higher level of lower extremity function and mobility (i.e., better self-reported health).

    3. Association between exercise patterns and well-being [Baseline]

      Association between exercise patterns (including exercise type and frequency) and well-being, as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire. The Neuro-QOL short form domain on Positive Affect and Well-Being will be used. The score range for the Neuro-QOL Positive Affect and Well-Being domain is 9 to 45, with higher scores reflecting a higher level of well-being.

    4. Association between exercise patterns and quality of life [2 years]

      Association between exercise patterns (including exercise type and frequency) and quality of life, as assessed by the Parkinson's Disease Questionnaire (PDQ-39). The score range for the PDQ-39 is 0 to 100, with lower scores reflecting higher quality of life.

    5. Association between exercise patterns and mobility [2 years]

      Association between exercise patterns (including exercise type and frequency) and mobility, as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire. The Neuro-QOL short form domain on Lower Extremity Function - Mobility will be used. The score range for the Neuro-QOL Mobility domain is 8 to 40, with higher scores reflecting a higher level of lower extremity function and mobility (i.e., better self-reported health).

    6. Association between exercise patterns and well-being [2 years]

      Association between exercise patterns (including exercise type and frequency) and well-being, as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire. The Neuro-QOL short form domain on Positive Affect and Well-Being will be used. The score range for the Neuro-QOL Positive Affect and Well-Being domain is 9 to 45, with higher scores reflecting a higher level of well-being.

    Secondary Outcome Measures

    1. Proportion of participants who attend a PD-specific exercise class [Baseline]

      Number of participants who attend a PD-specific exercise class relative to the total number of study participants.

    2. Frequency of participation in exercise classes or recreational exercise [Baseline]

      Frequency distribution of participation in exercise classes or recreational exercise, expressed on a weekly basis.

    3. Quality of Life score on the Parkinson's Disease Questionnaire (PDQ-39) [Baseline]

      Quality of Life summary index score on the Parkinson's Disease Questionnaire (PDQ-39). The score range for the PDQ-39 is 0 to 100, with lower scores reflecting higher quality of life.

    4. Mobility score on the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire [Baseline]

      Mobility score will be computed from the Quality of Life in Neurological Disorders (Neuro-QOL) short form questionnaire. The Neuro-QOL short form domain on Lower Extremity Function - Mobility will be used. The score range for the Neuro-QOL Mobility domain is 8-40, with higher scores reflecting a higher level of lower extremity function and mobility (i.e., better self-reported health).

    5. Well-being score on the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire [Baseline]

      Well-being will be assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire. The Neuro-QOL short form domain on Positive Affect and Well-Being will be used. The score range for the Neuro-QOL Positive Affect and Well-Being domain is 9 to 45, with higher scores reflecting a higher level of well-being.

    6. Proportion of participants who attend a PD-specific exercise class [2 years]

      Number of participants who attend a PD-specific exercise class relative to the total number of study participants.

    7. Frequency of participation in exercise classes or recreational exercise [2 years]

      Frequency distribution of participation in exercise classes or recreational exercise, expressed on a weekly basis.

    8. Quality of Life score on the Parkinson's Disease Questionnaire (PDQ-39) [2 years]

      Quality of Life summary index score on the Parkinson's Disease Questionnaire (PDQ-39). The score range for the PDQ-39 is 0 to 100, with lower scores reflecting higher quality of life.

    9. Mobility score on the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire [2 years]

      Mobility score will be computed from the Quality of Life in Neurological Disorders (Neuro-QOL) short form questionnaire. The Neuro-QOL short form domain on Lower Extremity Function - Mobility will be used. The score range for the Neuro-QOL Mobility domain is 8-40, with higher scores reflecting a higher level of lower extremity function and mobility (i.e., better self-reported health).

    10. Well-being score on the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire [2 years]

      Well-being will be assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) questionnaire. The Neuro-QOL short form domain on Positive Affect and Well-Being will be used. The score range for the Neuro-QOL Positive Affect and Well-Being domain is 9 to 45, with higher scores reflecting a higher level of well-being.

    Other Outcome Measures

    1. Age of participants (in years) [Baseline]

      Age of participants (years)

    2. Proportion of men and women [Baseline]

      Number of men and number of women relative to the total number of study participants

    3. State or country of residence [Baseline]

      State of residence (for those living in the United States) or country of residence (for those living outside the United States)

    4. Year of diagnosis of Parkinson Disease [Baseline]

      Year in which the participant was diagnosed as having Parkinson Disease

    5. Proportion of participants who tested positive for coronavirus [Baseline]

      Number of participants who tested positive for coronavirus relative to the total number of study participants. Coronavirus is the virus that causes coronavirus disease 2019 (COVID-19).

    6. Proportion of participants who have received a vaccine for coronavirus disease 2019 (COVID-19) [Baseline]

      Number of participants who have received a vaccine for coronavirus disease 2019 (COVID-19) relative to the total number of study participants.

    7. Proportion of participants who do not intend to receive a vaccine for coronavirus disease 2019 (COVID-19) [Baseline]

      Number of participants who do not intend to receive a vaccine for coronavirus disease 2019 (COVID-19) relative to the total number of study participants.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Diagnosis of Parkinson Disease

    • Ability to provide informed consent

    Exclusion Criteria:
    • Children (<18 years of age)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Washington University School of Medicine Saint Louis Missouri United States 63108

    Sponsors and Collaborators

    • Washington University School of Medicine

    Investigators

    • Principal Investigator: Susan B Racette, Ph.D., Washington University School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Washington University School of Medicine
    ClinicalTrials.gov Identifier:
    NCT04782518
    Other Study ID Numbers:
    • 202002075
    First Posted:
    Mar 4, 2021
    Last Update Posted:
    May 2, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Washington University School of Medicine
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 2, 2022